Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT03130426

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03130426
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03130426. Randomized; no masking; primary purpose treatment. Start 2017-06-27 (actual); primary completion 2019-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Acronym
REMIT-iGL
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
iGlarLixi
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Metformin
Intervention (Behavioral)
Lifestyle therapy
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03130426
Content hash
10bdf55ad848bc4223478d0025612978c28fe3c6da6ecb4aa9a04ca41fabed47